Myeloid Cells and Innate Immunity in Solid Tumors
Organizer(s): Judith A. Varner, Lisa M. Coussens and Dmitry I. Gabrilovich Date: September 21 - 23, 2020
Location: Virtual at your computer
For important information on the coronavirus, please click here
The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However, as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of cancer immune suppression and the field of cancer immune therapy forward. The objectives of this proposed conference are to present the latest developments in our understanding of the origins and contributions of various myeloid cell subsets to tumor growth and metastasis. Additionally, this conference will challenge paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function, and about mechanisms by which myeloid cells control immunity. The conference will also feature the latest clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations and advance development of new cancer immune therapeutics.
Global Health Travel Award Deadline: August 24 2020
Scholarship Deadline: August 24 2020
Abstract Deadline: September 3 2020
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA254451-01
Funding for this conference was made possible (in part) by 1R13CA254451-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.